Bristol-Myers Squibb’s Opdivo fails to meet key endpoint in small cell lung cancer trial
Bristol-Myers Squibb’s cancer drug Opdivo (nivolumab) has failed to meet the primary endpoint in the Phase 3 CheckMate -331 trial, designed to assess its effectiveness ... Read More
Synspira’s PAAG15A receives orphan drug designation for cystic fibrosis treatment
Synspira Therapeutics’ investigational inhaled treatment, PAAG15A, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of cystic ... Read More
MaaT Pharma commences HERACLES Phase 2 trial for MaaT013 in battle against acute graft-versus-host disease
MaaT Pharma, a French oncology company, has announced a significant milestone in its clinical research: the dosing of the first patient in the HERACLES Phase ... Read More
Bristol-Myers Squibb partners with Compugen to trial COM701 and Opdivo combination for advanced solid tumors
Bristol-Myers Squibb’s (BMS) latest clinical partnership with Israeli company Compugen is set to explore the efficacy of combining its leading cancer drug Opdivo (nivolumab) with ... Read More
Eyevance Pharmaceuticals acquires global rights for Nexagon from OcuNexus Therapeutics
Eyevance Pharmaceuticals has made a significant move in the ophthalmic drug market by acquiring the global licensing rights for Nexagon, an advanced antisense oligomer drug, ... Read More
GNI Group to halt enrolment in Phase 2 liver fibrosis trial following positive results
Japanese biotech company GNI Group has announced it will cease enrolment of new patients in its Phase 2 liver fibrosis trial for the drug candidate ... Read More
FDA approves once-weekly dosing for Amgen’s Kyprolis in multiple myeloma treatment
The United States Food and Drug Administration (FDA) has granted approval for a new once-weekly dosing regimen of Amgen's Kyprolis (carfilzomib) in combination with dexamethasone ... Read More
Five Prime Therapeutics and Zai Lab start Phase 3 study of bemarituzumab for advanced gastric cancer
California-based Five Prime Therapeutics and Chinese biopharma Zai Lab have initiated a pivotal Phase 3 trial of bemarituzumab (FPA144) in combination with chemotherapy for patients ... Read More
Alexion Pharmaceuticals to acquire Syntimmune for $1.2bn to boost rare disease drug pipeline
In a significant move within the pharmaceutical industry, Alexion Pharmaceuticals, a leading global biopharma company, has announced its acquisition of Syntimmune, a Boston-based clinical-stage biotech ... Read More
Taro Pharmaceutical ends licensing agreement with NovaBiotics over Novexatin failure
Taro Pharmaceutical Industries has terminated its licensing agreement with Scottish biotech company NovaBiotics concerning the Novexatin drug after disappointing clinical trial results. The decision follows ... Read More